Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2023-04-03 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于为全资子公司提供担保预计额度的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the provision of a guarantee (担保) for its wholly-owned subsidiary. It details the guarantee amount, internal decision procedures, financial data of the subsidiary, and board and independent director opinions. The document is relatively short (2261 characters) and focuses on a specific corporate action related to financing support rather than presenting comprehensive financial statements or audit results. It does not contain full financial reports or earnings data but is a formal disclosure of a capital/financing update related to guarantees provided by the parent company. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-04-03 Chinese
奥锐特药业股份有限公司关于前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by 奥锐特药业股份有限公司, including amounts raised, investment projects, actual investment versus committed amounts, and the benefits realized from these investments. It references regulatory approval from the China Securities Regulatory Commission and provides financial figures and project status as of September 30, 2022. The content focuses on the specific use and management of capital raised through a prior public offering, which aligns with a Capital/Financing Update. The document is not a general annual or interim report, nor is it an announcement or certification. It contains substantive financial data related to capital usage, making it a Capital/Financing Update (CAP).
2023-04-03 Chinese
奥锐特药业股份有限公司前次募集资金使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "前次募集资金使用情况鉴证报告" which translates to "Previous Fundraising Use Verification Report." It includes a verification report by a certified public accountant on the use of previously raised funds, detailed tables on the amounts raised, usage, investment projects, and their effectiveness up to September 30, 2022. The document references compliance with the China Securities Regulatory Commission guidelines for issuance and fundraising use. It is a standalone audit-type report focusing on the use of raised capital and its verification, not a full annual or interim financial report. It is not an announcement or a brief summary but a detailed verification report. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (12,161 characters) supports it being a full report rather than a brief announcement or certification letter. 9M 2022
2023-04-03 Chinese
奥锐特药业股份有限公司可转换公司债券持有人会议规则
Regulatory Filings Classification · 95% confidence The document is titled as "Convertible Corporate Bonds Holders Meeting Rules" for 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.). It details the rules and procedures for organizing and conducting meetings of holders of convertible bonds issued by the company. The content includes rights and obligations of bondholders, meeting convening procedures, voting rules, and legal compliance references. There is no financial data, earnings information, or report publication announcement. The document is a regulatory or governance-related procedural document concerning bondholder meetings and their governance. It does not fit into financial reports, earnings releases, or capital updates. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2023-04-03 Chinese
奥锐特药业股份有限公司向不特定对象发行可转换公司债券方案的论证分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report discussing the issuance of convertible corporate bonds by 奥锐特药业股份有限公司, a company listed on the Shanghai Stock Exchange. It includes extensive analysis on the necessity, pricing principles, legal compliance, issuance methods, and impact on shareholders. The content references relevant Chinese securities laws and regulations, detailed financial data, and procedural compliance for the bond issuance. The document is not a brief announcement but a comprehensive analysis and justification report for the convertible bond issuance. This fits the category of a Capital/Financing Update (CAP), as it provides an in-depth update on the company's financing activities and capital structure changes through convertible bond issuance.
2023-04-03 Chinese
奥锐特药业股份有限公司关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2023 first extraordinary general meeting of shareholders for 奥锐特药业股份有限公司. It includes the meeting date, voting methods, agenda items for shareholder approval, and instructions for proxy voting. The content focuses on the announcement and procedural details of the shareholder meeting rather than the meeting materials or results themselves. There is no financial data or report content, only the meeting notice and agenda. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2023-04-03 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.